



Emerging Biomarkers Used in Radiochemotherapy

Guest Editors:

Dr. Markus Schirmer

Department of Radiotherapy and
Radiation Oncology, University
Medicine Goettingen (UMG),
Robert-Koch-Str. 40, 37075
Goettingen, Germany

Prof. Dr. Stefan Rieken

Department of Radiotherapy and
Radiation Oncology, University
Medicine Goettingen (UMG),
Robert-Koch-Str. 40, 37075
Goettingen, Germany

Deadline for manuscript
submissions:

closed (31 March 2022)

Message from the Guest Editors

Dear colleagues,

Unlike great advances made in targeted chemotherapy by profiling tumors for addressable mutations, no such treatment individualization has been achieved yet for radiotherapy or combined radiochemotherapy. Given the broad spectra of both treatment outcomes and side-effects, a substantial impact of tumors and host biomarkers is presumed. With the rapid progress in the technical exploration of molecular features in the (epi-)genome, transcriptome, proteome, and metabolome there is an emerging potential for the discovery of promising biomarkers in radiochemotherapy. This Special Issue invites experts in this field to present and discuss data on prognostic and predictive biomarkers assessed in retrospective and prospective clinical cohorts with various kinds of radiotherapy or radiochemotherapy applied. Sophisticated data on functional mechanisms of biomarkers are also welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)